Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122760 | 1.00 | HCAR2 (0.43) | HCAR2TTRCYP3A4TSHRTDP1 | |
| SCHEMBL23040861 | 0.94 | HCAR2 (0.52) | HCAR2TTRCYP3A4TSHRTDP1 | |
| SCHEMBL9475517 | 0.94 | HCAR2 (0.52) | HCAR2TTRCYP3A4TSHRTDP1 | |
| SCHEMBL87888 | 0.94 | HCAR2 (0.52) | HCAR2TTRCYP3A4TSHRTDP1 | |
| SCHEMBL6053862 | 0.81 | CYP3A4 (0.43) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL9319210 | 0.79 | TTR (0.41) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL31668182 | 0.79 | TTR (0.41) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL31668175 | 0.79 | TTR (0.48) | TTRCYP3A4TSHRTDP1MEN1 | |
| SCHEMBL9319479 | 0.79 | TTR (0.41) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL7750809 | 0.78 | TTR (0.39) | TTRCYP3A4TSHRTDP1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341174-B | Succinyl cross-linked hemoglobin analogues and methods of use and preparation thereof | 亿京国际有限公司 | 2024-05-17 | — | — | CN | claimed |
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2024-01-02 | — | — | US | claimed |
| US-20220280616-A1 | Thiosuccinyl-crosslinked Hemoglobin Conjugates and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (HK) | 2022-09-08 | — | — | US | claimed |
| CN-114341174-A | Thiosuccinyl cross-linked hemoglobin analogs and methods of use and preparation thereof | 亿京国际有限公司 | 2022-04-12 | — | — | CN | claimed |
| EP-2968597-B1 | POLYALKYLENE OXIDE VALERATE HEMOGLOBIN CONJUGATES | SCHINDLER WILLIAM (US) | 2021-08-18 | — | — | EP | claimed |
| CN-112852772-A | Urate oxidase based on intramolecular cross-linking and polyethylene glycol modification and preparation method thereof | 中国科学院过程工程研究所 | 2021-05-28 | — | — | CN | claimed |
| EP-2830638-B1 | DIASPIRIN CROSSLINKED PEGYLATED HEMOGLOBIN | SCHINDLER WILLIAM (US) | 2021-05-05 | — | — | EP | claimed |
| US-20210061885-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2021-03-04 | — | — | US | claimed |
| US-10821158-B2 | Polyalkylene oxide valerate hemoglobin conjugates | Schindler, William (US) | 2020-11-03 | — | — | US | claimed |
| US-10029001-B2 | Diaspirin crosslinked pegylated hemoglobin | Schindler, William (US) | 2018-07-24 | — | — | US | claimed |
| US-8106011-B1 | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking | BILLION KING INTERNATIONAL LIMITED (HK) | 2012-01-31 | — | — | US | claimed |
| WO-2011162863-A1 | A METHOD FOR THE PREPARATION OF A HEAT STABLE OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION | WONG BING LOU (US) | 2011-12-29 | — | — | WO | claimed |
| US-20110319858-A1 | METHOD FOR THE PREPARATION OF A HEAT STABLE OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | BILLION KING INTERNATIONAL LIMITED (HK) | 2011-12-29 | — | — | US | claimed |
| EP-2399606-A1 | A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition | Wong, Bing Lou (US) | 2011-12-28 | — | — | EP | claimed |
| US-7932356-B1 | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition | BILLION KING INTERNATIONAL LIMITED (HK) | 2011-04-26 | — | — | US | claimed |
| US-5128452-A | Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate | BAXTER INTERNATIONAL INC. (US) | 1992-07-07 | — | — | US | claimed |
| US-5041615-A | Preparation of bis(salicyl) diesters | BAXTER INTERNATIONAL INC. (US) | 1991-08-20 | — | — | US | claimed |
| EP-0195558-B1 | COMPOSITION OF ALPHA-ALPHA- CROSS-LINKED HEMOGLOBINS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1990-05-23 | — | — | EP | claimed |
| EP-0195558-A2 | Composition of alpha-alpha- cross-linked hemoglobins | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1986-09-24 | — | — | EP | claimed |
| US-4598064-A | Alpha-alpha cross-linked hemoglobins | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1986-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029001-B2 | Diaspirin crosslinked pegylated hemoglobin | HBG2, HBG1, HBB | HCAR2 1401/4885TTR 162/4885CYP3A4 776/4885 |
| US-20210061885-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | HCAR2 3037/4885TTR 7/4885CYP3A4 818/4885 |
| US-10821158-B2 | Polyalkylene oxide valerate hemoglobin conjugates | HBZ, HBB, HBG1 | HCAR2 1186/4885TTR 11/4885CYP3A4 339/4885 |
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | HBG1, HBG2, HBB | HCAR2 3018/4885TTR 6/4885CYP3A4 1255/4885 |
| US-20220280616-A1 | Thiosuccinyl-crosslinked Hemoglobin Conjugates and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | HCAR2 3018/4885TTR 6/4885CYP3A4 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.